Furthermore, canavanine increased the phosphorylation of AMPK
measured using Western blot analysis in these isolated skeletal muscles in a dose-dependent manner.
Additionally, the insulin sensitivity of the diabetic rats was markedly increased by canavanine, and this
action was also blocked by BU224. Overall, canavanine is capable of activating imidazoline I-2R; I-2AR is
linked to an increase in the plasma level of b-endorphin, and I-2BR is related to effects on the glucose
uptake by skeletal muscle that reduces hyperglycemia in type 1-like diabetic rats. Therefore, canavanine
can be developed as effective agent to treat the diabetic disorders in the future.